In order to guide individualized treatment strategies and enhance the long-term outcomes, future longitudinal cohort studies and randomized controlled trials should examine the advantages, risks, and best use of GLP-1 receptor agonists for individual patients, especially considering the high prevalence of obesity and diabetes in HF populations. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.